Radius Health Inc (RDUS)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

ATTN: PRINCIPAL FINANCE OFFICER BOSTON, MA 02210

Radius Health Inc. is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine and other therapeutics. Radius' lead product, TYMLOS® (abaloparatide) injection, was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide transdermal system for potential use in the treatment of postmenopausal women with osteoporosis; the investigational drug, elacestrant (RAD1901), for potential use in the treatment of hormone-receptor positive breast cancer out-licensed to Menarini Group; and the investigational drug RAD011, a synthetic cannabidiol oral solution with potential utilization in multiple endocrine and metabolic orphan diseases, initially targeting Prader-Willi syndrome.

Data as of 2021-08-02 08:18:54 -0400
Market Cap714.781 Million Shares Outstanding47.243 Million Avg 30-day Volume279.422 Thousand
P/E Ratio-8.18736 Dividend Yield EPS-1.87
Price/Sales2.89 Debt to Equity-0.95 EBITDA-63.445 Million
Price to Book Value-3.31 Forward PE1.44 Enterprise Value938.156 Million
Total Cash114.124 Million Current Debt80.399 Million Gross Profit230.516 Million
BETA1.22802 52-week High/Low26.16 / 10.15 Next Earnings Date2021-08-05 Price to Cash FLow (P/CF) -54.3031
Data provided by IEX Cloud
View SEC Filings from RDUS instead.
Q1 2021 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 0 0 1 (0.06%) 2 (0.12%) -50.0%
Funds Holding: 138 131 5.34% 45 (2.64%) 42 (2.44%) 7.14%
13F shares: 48.941 Million 49.162 Million -0.45% 15.415 Million 17.428 Million -11.55%
% Ownership 32.8717 37.4419 -12.21%
New Positions: 24 17 41.18% 8 8 0.0%
Increased Positions 47 41 14.63% 13 11 18.18%
Closed Positions 17 16 6.25% 5 11 -54.55%
Reduced Positions 50 47 6.38% 20 17 17.65%
Total Calls 234.245 Thousand 134.424 Thousand 74.26% 114.1 Thousand 29.4 Thousand 288.1%
Total Puts 202.848 Thousand 137.582 Thousand 47.44% 40 Thousand 41.1 Thousand -2.68%
PUT/CALL Ratio 0.87 1.02 -14.71% 0.35 1.4 -75.0%
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding RDUS (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding RDUS BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

SHAH CHHAYA CHIEF BUSINESS OFFICER

  • Officer
19,645 2021-03-18 1

CHOPAS JAMES GEORGE PRINCIPAL FINANCE ACCOUNTING

  • Officer
6,701 2021-03-05 4

GRAUSSO SAL CHIEF COMMERCIAL OFFICER

  • Officer
11,709 2021-02-25 4

HUGHES OWEN

  • Director
26,150 2021-02-22 2

DERE WILLARD H

  • Director
27,695 2021-02-22 2

FRIEDMAN CATHY

  • Director
31,300 2021-02-22 2

GARNIER JEAN PIERRE

  • Director
31,300 2021-02-22 2

MARTIN G. KELLY CEO AND PRESIDENT

  • Officer
  • Director
460,000 2021-02-22 2

MURPHY SEAN

  • Director
15,500 2021-02-22 4

VON ESCHENBACH ANDREW C.

  • Director
0 2021-01-04 2

SANDERS MACHELLE

  • Director
0 2021-01-04 2

DOLAN DAN VP OF FINANCE

  • Officer
0 2020-11-09 2

BIOTECH TARGET N V

BB BIOTECH AG

  • 10% Owner
7,455,714 2020-11-05 1

ROSENBERG ANTHONY

  • Director
12,401 2020-02-26 0

CARMONA JOSE CHIEF FINANCIAL OFFICER

  • Officer
46,708 2020-02-26 0

KELLY JOSEPH FRANCIS SR. VP OF SALES AND MARKETING

  • Officer
24,111 2020-02-26 0

MORRIS CHARLES Q CHIEF MEDICAL OFFICER

  • Officer
33,744 2020-02-26 0

GRAVES KURT

  • Director
11,000 2020-02-20 0

HOEILAND JESPER PRESIDENT AND CEO

  • Officer
  • Director
0 2020-02-20 0

HOPFIELD JESSICA

  • Director
18,300 2020-02-20 0

BIOTECH GROWTH N V

BB BIOTECH AG

  • 10% Owner
6,881,685 2019-11-06 0

ROYCHOWDHURY DEBASISH

  • Director
5,500 2019-04-11 0

HATZIS-SCHOCH BRENT SR. VP, GENERAL COUNSEL

  • Officer
17,944 2019-02-22 0

HATTERSLEY GARY CHIEF SCIENTIFIC OFFICER

  • Officer
No longer subject to file 2018-12-31 0

FITZPATRICK LORRAINE A. CHIEF MEDICAL OFFICER

  • Officer
No longer subject to file 2018-12-31 0

WILLIAMS GREGORY C. CHIEF DEVELOPMENT OFFICER

  • Officer
0 2018-02-13 0

SNOW DAVID P. CHIEF COMMERCIAL OFFICER

  • Officer
No longer subject to file 2017-12-31 0

HARVEY BRIAN NICHOLAS SR. VP AND CFO

  • Officer
76,189 2017-04-25 0

GADICKE ANSBERT

  • Director
0 2017-02-17 0

AUERBACH ALAN H

  • Director
0 2017-02-17 0

WARD ROBERT PRESIDENT & CEO

  • Officer
  • Director
0 2017-02-17 0

PURANDARE DINESH SVP, HEAD OF GLOBAL ONCOLOGY

  • Officer
0 2017-02-17 0

MPM BIOVENTURES III LLC

HENNER DENNIS

MPM ASSET MANAGEMENT INVESTORS 2003 BVIII LLC

MPM BIOVENTURES III GMBH & CO. BETEILIGUNGS KG

MPM BIOVENTURES III PARALLEL FUND, L.P.

MPM BIOVENTURES III GP L.P.

MPM BIOVENTURES III L.P.

MPM BIOVENTURES III-QP L.P.

STEINMETZ MICHAEL

  • FORMER 10% STOCKHOLDERFORMER 10% STOCKHOLDERFORMER 10% STOCKHOLDERFORMER 10% STOCKHOLDERFORMER 10% STOCKHOLDERFORMER 10% STOCKHOLDERFORMER 10% STOCKHOLDERFORMER 10% STOCKHOLDERFORMER 10% STOCKHOLDER
No longer subject to file 2016-09-27 0

EVNIN LUKE

  • FORMER 10% STOCKHOLDER
No longer subject to file 2016-09-27 0

GALAKATOS NICHOLAS

SIMON NICHOLAS J III

WHEELER KURT

  • FORMER 10% STOCKHOLDERFORMER 10% STOCKHOLDERFORMER 10% STOCKHOLDER
No longer subject to file 2016-09-27 0

MPM BIOVENTURES IV LLC

SCOPA JAMES PAUL

MPM BIOVENTURES IV GP LLC

MPM BIO IV NVS STRATEGIC FUND LP

KAILIAN VAUGHN M

FOLEY TODD

  • FORMER 10% STOCKHOLDERFORMER 10% STOCKHOLDERFORMER 10% STOCKHOLDERFORMER 10% STOCKHOLDERFORMER 10% STOCKHOLDERFORMER 10% STOCKHOLDER
No longer subject to file 2016-09-27 0

WARD ROB PRESIDENT & CEO

  • Officer
  • Director
0 2015-10-21 0

MUENCHBACH MARTIN

  • Director
0 2015-05-07 0

F2 BIOSCIENCE IV L.P.

F2 BIOSCIENCE IV GP LTD.

F2 CAPITAL LTD

PRIESTLEY KATHERINE

F2 BIO VENTURES V L.P.

F2 BIO VENTURES GP LTD.

GLOBEWAYS HOLDINGS LTD

  • 10% Owner
No longer subject to file 2015-01-16 0

F2 BIOSCIENCE III, L.P.

F2 BIOSCIENCE GP LTD.

F2 CAPITAL LTD

PRIESTLEY KATHERINE

GLOBEWAYS HOLDINGS LTD

  • 10% Owner
No longer subject to file 2015-01-16 0

JOVAN-EMBIRICOS MORANA

  • Director
  • 10% Owner
3,834,831 2015-01-08 0

F2 BIOSCIENCE III, L.P.

F2 BIOSCIENCE GP LTD.

F2 CAPITAL LTD

PRIESTLEY KATHERINE

  • 10% Owner
1,167,997 2015-01-08 0

HARRIS ALAN G CHIEF MEDICAL OFFICER

  • Officer
0 2014-12-17 0

STONER ELIZABETH

  • Director
0 2014-12-17 0

F2 BIOSCIENCE VI L.P.

F2 CAPITAL LTD

PRIESTLEY KATHERINE

GLOBEWAYS HOLDINGS LTD

F2 BIOSCIENCE IV GP LTD.

  • 10% Owner
587,500 2014-06-11 0

F2 BIOSCIENCE IV L.P.

F2 BIOSCIENCE IV GP LTD.

F2 CAPITAL LTD

PRIESTLEY KATHERINE

F2 BIO VENTURES V L.P.

F2 BIO VENTURES GP LTD.

GLOBEWAYS HOLDINGS LTD

F2 BIOSCIENCE VI L.P.

  • 10% Owner
3,254,334 2014-06-11 0

DURAND MARK CHIEF COMMERCIAL OFFICER

  • Officer
0 2014-06-05 0

MPM BIOVENTURES IV LLC

SCOPA JAMES PAUL

VANDER VORT JOHN

MPM BIOVENTURES IV GP LLC

MPM BIO IV NVS STRATEGIC FUND LP

FOLEY TODD

KAILIAN VAUGHN M

  • 10% Owner
0 2013-04-23 0

WELLCOME TRUST LTD (THE) AS TRUSTEE OF THE WELLCOME TRUST

  • 10% Owner
0 2011-12-14 0

FLEMING JONATHAN

  • Director
0 2011-12-14 0

MPM BIOVENTURES IV LLC

MPM BIOVENTURES IV GP LLC

MPM BIO IV NVS STRATEGIC FUND LP

FOLEY TODD

KAILIAN VAUGHN M

SCOPA JAMES PAUL

ST PETER STEVEN

VANDER VORT JOHN

  • 10% Owner
0 2011-12-14 0

HEALTHCARE VENTURES VII LP

HEALTHCARE PARTNERS VII, L.P.

CAVANAUGH JAMES H

LAWLOR AUGUSTINE

LITTLECHILD JOHN W

MIRABELLI CHRISTOPHER

WERNER HAROLD R

  • 10% Owner
0 2011-11-18 0

LYTTLE CECIL RICHARD PRESIDENT AND CEO

  • Officer
  • Director
0 2011-11-07 0

O'DEA LOUIS SR. VP, CHIEF MEDICAL OFFICER

  • Officer
0 2011-11-07 0

MPM BIOVENTURES IV LLC

MPM BIOVENTURES IV GP LLC

MPM BIO IV NVS STRATEGIC FUND LP

DOMBKOWSKI ASHLEY L

GREENE WILLIAM

KAILIAN VAUGHN M

SCOPA JAMES PAUL

ST PETER STEVEN

VANDER VORT JOHN

  • 10% Owner
0 2011-05-17 0

IPSEN PHARMA SAS

IPSEN, S.A.

  • 10% Owner
  • POSSIBLE 10% BENEFICIAL OWNER
0 2011-05-17 0

ST PETER STEVEN PRESIDENT

  • Officer
  • Director
0 2008-06-15 0

VANDER VORT JOHN SECRETARY

  • Officer
  • Director
0 2008-06-15 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
RADIUS HEALTH INC RDUS 2021-08-05 22:15:04 UTC -0.55 0.63 400000
RADIUS HEALTH INC RDUS 2021-08-05 21:45:03 UTC -0.55 0.63 400000
RADIUS HEALTH INC RDUS 2021-08-05 21:15:03 UTC -0.55 0.63 400000
RADIUS HEALTH INC RDUS 2021-08-05 20:45:03 UTC -0.55 0.63 400000
RADIUS HEALTH INC RDUS 2021-08-05 20:15:04 UTC -0.55 0.63 400000
RADIUS HEALTH INC RDUS 2021-08-05 19:45:04 UTC -0.55 0.63 400000
RADIUS HEALTH INC RDUS 2021-08-05 19:15:03 UTC -0.55 0.63 400000
RADIUS HEALTH INC RDUS 2021-08-05 18:45:03 UTC -0.55 0.63 400000
RADIUS HEALTH INC RDUS 2021-08-05 18:15:03 UTC -0.55 0.63 400000
RADIUS HEALTH INC RDUS 2021-08-05 17:45:03 UTC -0.55 0.63 400000
RADIUS HEALTH INC RDUS 2021-08-05 17:15:03 UTC -0.55 0.63 400000
RADIUS HEALTH INC RDUS 2021-08-05 16:45:02 UTC -0.55 0.63 400000
RADIUS HEALTH INC RDUS 2021-08-05 16:15:03 UTC -0.55 0.63 400000
RADIUS HEALTH INC RDUS 2021-08-05 15:45:03 UTC -0.55 0.63 400000
RADIUS HEALTH INC RDUS 2021-08-05 15:15:02 UTC -0.55 0.63 400000
RADIUS HEALTH INC RDUS 2021-08-05 14:45:02 UTC -0.55 0.63 400000
RADIUS HEALTH INC RDUS 2021-08-05 14:15:04 UTC -0.55 0.63 400000
RADIUS HEALTH INC RDUS 2021-08-05 13:45:04 UTC -0.55 0.63 400000
RADIUS HEALTH INC RDUS 2021-08-05 13:15:03 UTC -0.55 0.63 400000
RADIUS HEALTH INC RDUS 2021-08-05 12:45:03 UTC -0.55 0.63 400000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
AMERICAN BEACON FUNDS- American Beacon SSI Alternative Income Fund RDUS -8768.0 shares, $-182900.48 2021-03-31 N-PORT
Morningstar Funds Trust- Morningstar Alternatives Fund RDUS -4191.0 shares, $-93459.3 2021-04-30 N-PORT

Elevate your investments